Ro B I
Department of Dermatology, Yongsan Hospital, College of Medicine, Chung Ang University, Seoul, Korea.
J Dermatol. 1995 Nov;22(11):858-64. doi: 10.1111/j.1346-8138.1995.tb03936.x.
I clinically studied 905 patients with alopecia areata (AA) who visited the Department of Dermatology, College of Medicine, Chung Ang University, from January of 1982 to February of 1994. The purpose of the study was to evaluate the clinical manifestations and compare the effects of treatment with intralesional injection of triamcinolone acetonide suspension and immunotherapy with dinitrochlorobenzene (DNCB) or diphenylcyclopropenone (DPCP). The results were as follows: 1) The incidence of AA among all out-patients (59,970) was 1.5% (905 cases), and the ratio of males to females was 1.3:1 (512:393). 2) The age distribution showed high incidences in the third (41.8%) and fourth decades (20.0%). 3) The family history was contributory in 104 cases (11.5%). 4) The relapse rate was 17.5% (158 cases). 5) Almost half of the patients had a solitary lesion (408 cases, 46.7%). 6) The most common site of predilection was the occipital region of the scalp in both male and female patients. 7) Associated diseases were seborrheic dermatitis, atopic dermatitis, hepatitis, hypertension, open heart surgery, thyroid disease, pulmonary disease, and vitiligo in order of frequency. 8) The effect of treatment on the patients who had bald patches less than 50 cm2 was not significantly statistically different between intralesional injection of triamcinolone acetonide and immunotherapy with DNCB or DPCP. 9) In cases with bald areas more than 50 cm2, including alopecia totalis and universalis, DNCB or DPCP immunotherapy showed better therapeutic effects than did intralesional injection of triamcinolone acetonide.
1982年1月至1994年2月期间,我对905例斑秃(AA)患者进行了临床研究,这些患者均就诊于中央大学医学院皮肤科。本研究旨在评估临床表现,并比较曲安奈德混悬液皮损内注射治疗与二硝基氯苯(DNCB)或二苯环丙烯酮(DPCP)免疫治疗的效果。结果如下:1)在所有门诊患者(59,970例)中,斑秃的发病率为1.5%(905例),男女比例为1.3:1(512:393)。2)年龄分布显示,第三(41.8%)和第四(20.0%)个十年发病率较高。3)104例(11.5%)有家族史。4)复发率为17.5%(158例)。5)几乎一半的患者有单个皮损(408例,46.7%)。6)男女患者最常见的好发部位均为头皮枕部。7)相关疾病依次为脂溢性皮炎、特应性皮炎、肝炎、高血压、心脏直视手术、甲状腺疾病、肺部疾病和白癜风。8)对于秃斑面积小于50 cm²的患者,曲安奈德皮损内注射与DNCB或DPCP免疫治疗的疗效在统计学上无显著差异。9)对于秃斑面积大于50 cm²的病例,包括全秃和普秃,DNCB或DPCP免疫治疗的疗效优于曲安奈德皮损内注射。